2,721 results on '"Garg, Amit X."'
Search Results
2. Comparison of COVID-19 Hospitalization and Death Between Solid Organ Transplant Recipients and the General Population in Canada, 2020–2022
- Author
-
Naylor, Kyla L., Knoll, Gregory A., Treleaven, Darin, Kang, Yuguang, Garg, Amit X., Stirling, Kathryn, and Kim, S. Joseph
- Published
- 2024
- Full Text
- View/download PDF
3. Defining pre-emptive living kidney donor transplantation as a quality indicator
- Author
-
Wang, Carol, Garg, Amit X., Luo, Bin, Kim, S. Joseph, Knoll, Gregory, Yohanna, Seychelle, Treleaven, Darin, McKenzie, Susan, Ip, Jane, Cooper, Rebecca, Elliott, Lori, and Naylor, Kyla L.
- Published
- 2024
- Full Text
- View/download PDF
4. Risk Factors for Developing Low Estimated Glomerular Filtration Rate and Albuminuria in Living Kidney Donors
- Author
-
Dhalla, Anisha, Ravani, Pietro, Quinn, Robert R., Garg, Amit X., Clarke, Alix, Al-Wahsh, Huda, Lentine, Krista L., Klarenbach, Scott, Hemmelgarn, Brenda R., Wang, Carol, and Lam, Ngan N.
- Published
- 2024
- Full Text
- View/download PDF
5. One-year Outcomes after Discharge from Noncardiac Surgery and Association between Predischarge Complications and Death after Discharge: Analysis of the VISION Prospective Cohort Study
- Author
-
Roshanov, Pavel S., Chan, Matthew T. V., Borges, Flavia K., Conen, David, Wang, C. Y., Xavier, Denis, Berwanger, Otavio, Marcucci, Maura, Sessler, Daniel I., Szczeklik, Wojciech, Spence, Jessica, Alonso-Coello, Pablo, Fernández, Carmen, Pearse, Rupert M., Malaga, German, Garg, Amit X., Srinathan, Sadeesh K., Jacka, Michael J., Tandon, Vikas, McGillion, Michael, Popova, Ekaterine, Sigamani, Alben, Abraham, Valsa, Biccard, Bruce M., Villar, Juan Carlos, Chow, Clara K., Polanczyk, Carísi A., Tiboni, Maria, Whitlock, Richard, Ackland, Gareth L., Panju, Mohamed, Lamy, André, Sapsford, Robert, Williams, Colin, Wu, William Ka Kei, Cortés, Olga L., MacNeil, S. Danielle, Patel, Ameen, Belley-Côté, Emilie P., Ofori, Sandra, McIntyre, William F., Leong, Darryl P., Heels-Ansdell, Diane, Gregus, Krysten, and Devereaux, P. J.
- Published
- 2024
- Full Text
- View/download PDF
6. Achieved blood pressure post-acute kidney injury and risk of adverse outcomes after AKI: A prospective parallel cohort study.
- Author
-
McCoy, Ian, Brar, Sandeep, Liu, Kathleen D, Go, Alan S, Hsu, Raymond K, Chinchilli, Vernon M, Coca, Steven G, Garg, Amit X, Himmelfarb, Jonathan, Ikizler, T Alp, Kaufman, James, Kimmel, Paul L, Lewis, Julie B, Parikh, Chirag R, Siew, Edward D, Ware, Lorraine B, Zeng, Hui, Hsu, Chi-Yuan, and Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study investigators
- Subjects
Assessment ,Serial Evaluation ,and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study investigators ,AKI ,blood pressure ,hypertension ,Kidney Disease ,Cardiovascular ,Clinical Research ,Patient Safety ,2.1 Biological and endogenous factors ,2.4 Surveillance and distribution ,Renal and urogenital ,Urology & Nephrology ,Clinical Sciences - Abstract
BackgroundThere has recently been considerable interest in better understanding how blood pressure should be managed after an episode of hospitalized AKI, but there are scant data regarding the associations between blood pressure measured after AKI and subsequent adverse outcomes. We hypothesized that among AKI survivors, higher blood pressure measured three months after hospital discharge would be associated with worse outcomes. We also hypothesized these associations between blood pressure and outcomes would be similar among those who survived non-AKI hospitalizations.MethodsWe quantified how systolic blood pressure (SBP) observed three months after hospital discharge was associated with risks of subsequent hospitalized AKI, loss of kidney function, mortality, and heart failure events among 769 patients in the prospective ASSESS-AKI cohort study who had hospitalized AKI. We repeated this analysis among the 769 matched non-AKI ASSESS-AKI enrollees. We then formally tested for AKI interaction in the full cohort of 1538 patients to determine if these associations differed among those who did and did not experience AKI during the index hospitalization.ResultsAmong 769 patients with AKI, 42 % had subsequent AKI, 13 % had loss of kidney function, 27 % died, and 18 % had heart failure events. SBP 3 months post-hospitalization did not have a stepwise association with the risk of subsequent AKI, loss of kidney function, mortality, or heart failure events. Among the 769 without AKI, there was also no stepwise association with these risks. In formal interaction testing using the full cohort of 1538 patients, hospitalized AKI did not modify the association between post-discharge SBP and subsequent risks of adverse clinical outcomes.ConclusionsContrary to our first hypothesis, we did not observe that higher stepwise blood pressure measured three months after hospital discharge with AKI was associated with worse outcomes. Our data were consistent with our second hypothesis that the association between blood pressure measured three months after hospital discharge and outcomes among AKI survivors is similar to that observed among those who survived non-AKI hospitalizations.
- Published
- 2021
7. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events
- Author
-
Menez, Steven, Wen, Yumeng, Xu, Leyuan, Moledina, Dennis G., Thiessen-Philbrook, Heather, Hu, David, Obeid, Wassim, Bhatraju, Pavan K., Ikizler, T. Alp, Siew, Edward D., Chinchilli, Vernon M., Garg, Amit X., Go, Alan S., Liu, Kathleen D., Kaufman, James S., Kimmel, Paul L., Himmelfarb, Jonathan, Coca, Steven G., Cantley, Lloyd G., and Parikh, Chirag R.
- Published
- 2023
- Full Text
- View/download PDF
8. Biomarkers of inflammation and repair in kidney disease progression
- Author
-
Puthumana, Jeremy, Thiessen-Philbrook, Heather, Xu, Leyuan, Coca, Steven G, Garg, Amit X, Himmelfarb, Jonathan, Bhatraju, Pavan K, Ikizler, Talat Alp, Siew, Edward, Ware, Lorraine B, Liu, Kathleen D, Go, Alan S, Kaufman, James S, Kimmel, Paul L, Chinchilli, Vernon M, Cantley, Lloyd, and Parikh, Chirag R
- Subjects
Kidney Disease ,Clinical Research ,4.2 Evaluation of markers and technologies ,2.1 Biological and endogenous factors ,Detection ,screening and diagnosis ,Aetiology ,Renal and urogenital ,Acute Kidney Injury ,Aged ,Animals ,Biomarkers ,Chemokine CCL2 ,Chitinase-3-Like Protein 1 ,Disease Models ,Animal ,Disease Progression ,Female ,Follow-Up Studies ,Glomerular Filtration Rate ,Humans ,Inflammation ,Male ,Mice ,Middle Aged ,Renal Insufficiency ,Chronic ,Chronic kidney disease ,Clinical practice ,Molecular diagnosis ,Nephrology ,Medical and Health Sciences ,Immunology - Abstract
INTRODUCTIONAcute kidney injury and chronic kidney disease (CKD) are common in hospitalized patients. To inform clinical decision making, more accurate information regarding risk of long-term progression to kidney failure is required.METHODSWe enrolled 1538 hospitalized patients in a multicenter, prospective cohort study. Monocyte chemoattractant protein 1 (MCP-1/CCL2), uromodulin (UMOD), and YKL-40 (CHI3L1) were measured in urine samples collected during outpatient follow-up at 3 months. We followed patients for a median of 4.3 years and assessed the relationship between biomarker levels and changes in estimated glomerular filtration rate (eGFR) over time and the development of a composite kidney outcome (CKD incidence, CKD progression, or end-stage renal disease). We paired these clinical studies with investigations in mouse models of renal atrophy and renal repair to further understand the molecular basis of these markers in kidney disease progression.RESULTSHigher MCP-1 and YKL-40 levels were associated with greater eGFR decline and increased incidence of the composite renal outcome, whereas higher UMOD levels were associated with smaller eGFR declines and decreased incidence of the composite kidney outcome. A multimarker score increased prognostic accuracy and reclassification compared with traditional clinical variables alone. The mouse model of renal atrophy showed greater Ccl2 and Chi3l1 mRNA expression in infiltrating macrophages and neutrophils, respectively, and evidence of progressive renal fibrosis compared with the repair model. The repair model showed greater Umod expression in the loop of Henle and correspondingly less fibrosis.CONCLUSIONSBiomarker levels at 3 months after hospitalization identify patients at risk for kidney disease progression.FUNDINGNIH.
- Published
- 2021
9. A prospective cohort study of acute kidney injury and kidney outcomes, cardiovascular events, and death.
- Author
-
Ikizler, T Alp, Parikh, Chirag R, Himmelfarb, Jonathan, Chinchilli, Vernon M, Liu, Kathleen D, Coca, Steven G, Garg, Amit X, Hsu, Chi-Yuan, Siew, Edward D, Wurfel, Mark M, Ware, Lorraine B, Faulkner, Georgia Brown, Tan, Thida C, Kaufman, James S, Kimmel, Paul L, Go, Alan S, and ASSESS-AKI Study Investigators
- Subjects
ASSESS-AKI Study Investigators ,Kidney ,Humans ,Cardiovascular Diseases ,Glomerular Filtration Rate ,Aftercare ,Patient Discharge ,Risk Factors ,Prospective Studies ,Adult ,Acute Kidney Injury ,acute kidney injury ,acute renal failure ,cardiovascular disease ,chronic kidney disease ,heart failure ,mortality ,Cardiovascular ,Clinical Research ,Kidney Disease ,Aging ,Renal and urogenital ,Urology & Nephrology ,Clinical Sciences - Abstract
Acute kidney injury (AKI) has been reported to be associated with excess risks of death, kidney disease progression and cardiovascular events although previous studies have important limitations. To further examine this, we prospectively studied adults from four clinical centers surviving three months and more after hospitalization with or without AKI who were matched on center, pre-admission CKD status, and an integrated priority score based on age, prior cardiovascular disease or diabetes mellitus, preadmission estimated glomerular filtration rate (eGFR) and treatment in the intensive care unit during the index hospitalization between December 2009-February 2015, with follow-up through November 2018. All participants had assessments of kidney function before (eGFR) and at three months and annually (eGFR and proteinuria) after the index hospitalization. Associations of AKI with outcomes were examined after accounting for pre-admission and three-month post-discharge factors. Among 769 AKI (73% Stage 1, 14% Stage 2, 13% Stage 3) and 769 matched non-AKI adults, AKI was associated with higher adjusted rates of incident CKD (adjusted hazard ratio 3.98, 95% confidence interval 2.51-6.31), CKD progression (2.37,1.28-4.39), heart failure events (1.68, 1.22-2.31) and all-cause death (1.78, 1.24-2.56). AKI was not associated with major atherosclerotic cardiovascular events in multivariable analysis (0.95, 0.70-1.28). After accounting for degree of kidney function recovery and proteinuria at three months after discharge, the associations of AKI with heart failure (1.13, 0.80-1.61) and death (1.29, 0.84-1.98) were attenuated and no longer significant. Thus, assessing kidney function recovery and proteinuria status three months after AKI provides important prognostic information for long-term clinical outcomes.
- Published
- 2021
10. Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes
- Author
-
Bhatraju, Pavan K., Prince, David K., Mansour, Sherry, Ikizler, T. Alp, Siew, Edward D., Chinchilli, Vernon M., Garg, Amit X., Go, Alan S., Kaufman, James S., Kimmel, Paul L., Coca, Steve G., Parikh, Chirag R., Wurfel, Mark M., and Himmelfarb, Jonathan
- Published
- 2023
- Full Text
- View/download PDF
11. Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada
- Author
-
Ha, Jeffrey T., Scaria, Anish, Andrade, Jason, Badve, Sunil V., Birks, Peter, Bota, Sarah E., Campain, Anna, Djurdjev, Ognjenka, Garg, Amit X., Harel, Ziv, Hemmelgarn, Brenda, Hockham, Carinna, James, Matthew T., Jardine, Meg J., Lam, Dickson, Levin, Adeera, McArthur, Eric, Ravani, Pietro, Shao, Selena, Sood, Manish M., Tan, Zhi, Tangri, Navdeep, Whitlock, Reid, Gallagher, Martin, and Jun, Min
- Published
- 2023
- Full Text
- View/download PDF
12. Covariate-Constrained Randomization
- Author
-
Al-Jaishi, Ahmed, primary, Dixon, Stephanie, additional, and Garg, Amit X., additional
- Published
- 2023
- Full Text
- View/download PDF
13. Rationale and design of the colchicine for the prevention of perioperative atrial fibrillation in patients undergoing major noncardiac thoracic surgery (COP-AF) trial
- Author
-
Devereaux, Vincent, Jessica, Wang, Michael Ke, Wells, Jennifer R., Conen, David, Devereaux, PJ, Healey, Jeff S., Landoni, Giovanni, McIntyre, William F., Popova, Ekaterine, Sessler, Daniel I., Srinathan, Sadeesh K., Amir, Mohammed, Bangdiwala, Shrikant I., Bossard, Matthias, Chan, Matthew T.V., Eikelboom, John W., Fleischmann, Edith, Jolly, Sanjit S., Montes, Felix Ramón, Reimer, Cara, Schmartz, Denis, Wang, Chew Yin, Alvarez-Garcia, Jesus, Bianco, Giuliana Lo, Blum, Steffen, Boasquevisque, Danielle de Sa, Borges, Flavia K., Chiarella-Redfern, Helene, Gonzalez-Osuna, Aranzazu, Guerra-Ramos, Jose M., Marcucci, Maura, Meyre, Pascal B., Ofori, Sandra N., Oleynick, Christopher, Ramos-Pachón, Anna, Traquair, Hugh, Mitchell, L. Brent, Wyse, George, Cheng, Davy, McAlister, Finlay A., Wells, George A., Baskaran, Geethan, Gennaccaro, Julia, Howe, Rosemary, Mastrangelo, Louise, Pettit, Shirley, Shahbaz, Subana, Tosh, Makayla, Zucchetto, Simona J., Heenan, Laura, Lee, Shun Fu, Li, Zhuoru, Xu, Lizhen, Kabon, Barbara, Reiterer, Christian, Taschner, Alexander, Horvath, Katharina, Adamowitsch, Nikolas, Zotti, Oliver, Hantáková, Nicole, Hochreiter, Beatrix, Huybrechts, Isabelle, Cappeliez, Serge, Neary, John D., Shargall, Yaron, Tandon, Vikas, Finley, Christian, Agzarian, John, Hanna, Waël, Abdulrahman, Muammar, Lawrence, Kelly, Gregus, Krysten, Quraishi, Faraaz, Wikkerink, Spencer, Wallace, Christine, Prine, Merissa, Gregus, Emily, Hare, Jacqueline, Lombardo, Kristen, Fezia, Behashta, Columbus, Teresa, DuMerton, Deborah, Reid, Ken, Parlow, Joel, Chung, Wiley, Karizhenskaia, Maria, Malik, Aftab, Kidane, Biniam, Liu, Richard, Tan, Lawrence, Gowing, Stephen, Buduhan, Gordon, Enns, Stephanie, Poole, Emma, Graham, Kristin, McLean, Sean R., McGuire, Anna, Lohser, Jens, Lim, Shirley, Grey, Rebecca, Grant, Kyle, Lee, Alex L., Choi, James J., Dewar, Leith R., Yee, John, Maziak, Donna E., Seely, Andrew J.E., Gilbert, Sebastien, Villeneuve, P. James, Sundaresan, Sudhir, Moffatt-Bruce, Susan D., Gingrich, Molly, Fazekas, Anna, Bucciero, Kirby, Malthaner, Richard A., Lewis, Deb, Fortin, Dalilah, Qiabi, Mehdi, Nayak, Rahul, Plourde, Madelaine Marie, Sellers, Daniel, Donahoe, Laura, Lefebvre, Marco, Lanthier, Luc, Schieman, Colin, Bessissow, Amal, Joynt, Gavin M., Wong, Randolph H.L., Lau, Rainbow W.H., Wong, Wai Tat, Choi, Gordon Y.S., Lee, Eva, Hui, Ka Yan, Fung, Beaker, Chan, Chee Sam, Gutiérrez-Soriano, Laura, Castañeda, Laura Carmenza, Téllez, Luis Jaime, Ortiz-Ramirez, Lina Marcela, De Santis, Simona, Favaro, Giovanni, Muriana, Piergiorgio, Nakhnoukh, Cristina, Novellis, Pierluigi, Turi, Stefano, Veronesi, Giulia, Angelini, Matteo, Voltolini, Luca, Bongiolatti, Stefano, Salvicchi, Alberto, Gatteschi, Lavinia, Indino, Rossella, Tombelli, Simone, Ravasin, Alice, Salimbene, Ottavia, Rosboch, Giulio Luca, Balzani, Eleonora, Massullo, Domenico, Fiorelli, Silvia, Londero, Francesco, Grossi, William, Ng, Tyng Yan, See, Woan Shiang, Nawaz, Mohammed Asghar, Reyes, Juan Carlos Trujillo, Tellez, Elisabeth Martinez, Sanchis, Josep Belda, Cánovas, Georgina Planas, Ruiz, Ana Parera, Gutierrez, Esther Cladellas, Guarino, Mauro, Cuchi, Gerard Urrutia, Nogues, Marta Argilaga, Juan, Anna Rovira, Medina-Aedo, Melixa, Grande, Ascensión Martín, Roux, Diego Parise, Martín, Luis Gajate, Pajares, Angélica De Pablo, Toha, Angel Manuel Candela, Mata, Nicolás Moreno, Molina, Gema Muñoz, Silva, Usue Caballero, Cabañero, Alberto, Fernandez, Sara Fra, Tallada, Anna Gonzàlez, Suarez, Susana González, Ball, Montserrat Ribas, Clanchet, Miriam De Nadal, Ruiz-Villa, Laura, Martí-Ejarque, M.M., Gili-Bueno, Mireia, Ferrández, Jorge Hernández, Llobet, Neus Pons, Cruz, Patricia, Sánchez-Pedrosa, Guillermo, Duque, Patricia, Azcárate, Leire, Martín-Albo, Lorena, Rodríguez-Fuster, Alberto, Bermejo-Martínez, Silvia, Carramiñana, Albert, Minervini, Fabrizio, Cata, Juan P., Rajaram, Ravi, Corrales, German, Guerra-Londono, Juan Jose, Mehran, Reza, Sepesi, Boris, Walsh, Garrett, Cukierman, Daniel S., Marchant, Bryan E., Harris, Lynne C., Cusson, Bruce D., Miller, Scott A., Minear, Steven C., Teixeira, Camila, Pimentel, Mario, Popoff, Andrew M., Cheung, Wing Lee, Marsack, Kelly, Ayad, Sabry, Araujo, Jorge, Chen, Tzonghuei H., Essandoh, Michael, Poppers, Jeremy S., Trujillo Reyes, Juan Carlos, Gonzalez Tallada, Anna, and Garg, Amit X.
- Published
- 2023
- Full Text
- View/download PDF
14. Prescription patterns of opioids and non‐steroidal anti‐inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records
- Author
-
Vest, Luke S, Sarabu, Nagaraju, Koraishy, Farrukh M, Nguyen, Minh‐Tri, Park, Meyeon, Lam, Ngan N, Schnitzler, Mark A, Axelrod, David, Hsu, Chi Yuan, Garg, Amit X, Segev, Dorry L, Massie, Allan B, Hess, Gregory P, Kasiske, Bertram L, and Lentine, Krista L
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Analgesics ,Opioid ,Anti-Inflammatory Agents ,Non-Steroidal ,Female ,Humans ,Kidney ,Kidney Transplantation ,Living Donors ,Male ,Pharmaceutical Preparations ,Pharmacy ,Registries ,donors and donation ,epidemiology ,living kidney donor ,pain management ,pharmacy records ,registries ,Clinical Sciences ,Surgery ,Clinical sciences - Abstract
We examined a novel database linking national donor registry identifiers to records from a US pharmaceutical claims warehouse (2007-2015) to describe opioid and NSAID prescription patterns among LKDs during the first year postdonation, divided into three periods: 0-14 days, 15-182 days, and 183-365 days. Associations of opioid and NSAID prescription fills with baseline factors were examined by logistic regression (adjusted odds ratio, LCL aORUCL ). Among 23,565 donors, opioid prescriptions were highest during days 0-14 (36.6%), but 12.6% of donors filled opioids during days 183-365. NSAID prescriptions rose from 0.5% during days 0-14 to 3.3% during days 183-365. Women filled opioids more commonly than men, and black donors filled both opioids and NSAIDs more commonly than white donors. After covariate adjustment, significant correlates of opioid prescription fills during days 183-365 included obesity (aOR,1.24 1.381.53 ), less than college education (aOR,1.19 1.311.43 ), smoking (aOR,1.33 1.451.58 ), and nephrectomy complications (aOR,1.11 1.291.49 ). NSAID prescription fills in year 1 were not associated with differences in estimated glomerular filtration rate, incidence of proteinuria or new-onset hypertension at the first and second year postdonation. Prescription fills for opioids and NSAIDs for LKDs varied with demographic and clinic traits. Future work should examine longer-term outcome implications to help inform safe analgesic regimen choices after donation.
- Published
- 2020
15. Mechanical versus bioprosthetic valves in chronic dialysis: a systematic review and meta-analysis
- Author
-
Kim, Kevin S., Belley-Cote, P. Emilie, Gupta, Saurabh, Pandey, Arjun, Alsagheir, Ali, Makhdoum, Ahmad, McClure, Graham, Newsome, Brooke, Gao, Sophie W., Bossard, Matthias, Isayama, Tetsuya, Ikuta, Yasuhisa, Walsh, Michael, Garg, Amit X., Guyatt, Gordon H., and Whitlock, Richard P.
- Subjects
Chronic kidney failure -- Complications and side effects ,Surgical research ,Heart valve prosthesis -- Comparative analysis -- Patient outcomes ,Surgery, Experimental ,Hemodialysis patients -- Care and treatment ,Heart valve replacement -- Patient outcomes ,Health ,Health care industry - Abstract
Background: Many patients with end-stage kidney disease (ESKD) have valvular heart disease requiring surgery. The optimal prosthetic valve is not established in this population. We performed a systematic review and meta-analysis to assess outcomes of patients with dialysis-dependent ESKD who received mechanical or bioprosthetic valves. Methods: We searched Cochrane Central, Medline and Embase from inception to January 2020. We performed screening, full-text assessment, risk of bias and data collection, independently and in duplicate. Data were pooled using a random-effects model. Results: We identified 28 observational studies (n = 9857 patients, including 6680 with mechanical valves and 3717 with bioprosthetic valves) with a median follow-up of 3.45 years. Twenty-two studies were at high risk of bias and 1 was at critical risk of bias from confounding. Certainty in evidence was very low for all outcomes except bleeding. Mechanical valves were associated with reduced mortality at 30 days (relative risk [RR] 0.79, 95% confidence interval [CI] 0.65-0.97, [I.sup.2] = 0, absolute effect 27 fewer deaths per 1000) and at 6 or more years (mean 9.7 yr, RR 0.83, 95% CI 0.72-0.96, [I.sup.2] = 79%, absolute effect 145 fewer deaths per 1000), but increased bleeding (incidence rate ratio [IRR] 2.46, 95% CI 1.41-4.27, [I.sup.2] = 59%, absolute effect 91 more events per 1000) and stroke (IRR 1.63, 95% CI 1.21-2.20, [I.sup.2] = 0%, absolute effect 25 more events per 1000). Conclusion: Mechanical valves were associated with reduced mortality, but increased rate of bleeding and stroke. Given very low certainty for evidence of mortality and stroke outcomes, patients and clinicians may choose prosthetic valves based on factors such as bleeding risk and valve longevity. Study registration: PROSPERO no. CRD42017081863 Contexte : De nombreux patients souffrant d'insuffisance renale terminale (IRT) presentent une valvulopathie necessitant une intervention chirurgicale. On ignore quelle est la valve prothetique optimale chez cette population. Nous avons effectue un examen systematique et une meta-analyse pour evaluer les resultats des patients atteints d'IRT dialyses ayant recu une valvule mecanique ou une bioprothese valvulaire. Methodes : Nous avons interroge les bases de donnees Cochrane Central, Medline et Embase, de leur date de creation jusqu'a janvier 2020. Nous avons procede a la selection, a l'evaluation des textes integraux, a l'evaluation des risques de biais et a la collecte de donnees, independamment et en double. Les donnees ont ete regroupees a l'aide d'un modele a effets aleatoires. Resultats : Nous avons cible 28 etudes d'observation (n = 9857 patients, dont 6680 avec une valvule mecanique et 3717 avec une bioprothese valvulaire), avec un suivi d'une duree mediane de 3,45 ans. Vingt-deux etudes presentaient un risque eleve de biais et 1 etude presentait un risque critique de biais resultant de variables de confusion. La certitude des donnees etait tres faible pour tous les resultats, a l'exception des hemorragies. Les valvules mecaniques ont ete associees a une reduction de la mortalite a 30 jours (risque relatif [RR] de 0,79, intervalle de confiance [IC] de 95 % 0,65-0,97, [I.sup.2] = 0, effet absolu de 27 deces de moins pour 1000 patients) et a 6 ans ou plus (moyenne de 9,7 ans, RR de 0,83, IC de 95 % 0,72-0,96, [I.sup.2] = 79 %, effet absolu de 145 deces de moins pour 1000 patients), mais egalement a une augmentation des hemorragies (rapport des taux d'incidence [RTI] de 2,46, IC de 95 % 1,41-4,27, [I.sup.2] = 59 %, effet absolu de 91 evenements supplementaires pour 1000 patients) et des AVC (IRR de 1,63, IC de 95 % 1,21-2,20, [I.sup.2] = 0 %, effet absolu de 25 evenements supplementaires pour 1000 patients). Conclusion : Les valvules mecaniques ont ete associees a une reduction de la mortalite, mais a une augmentation du taux d'evenements hemorragiques et d'AVC. Compte tenu du tres faible degre de certitude des donnees sur la mortalite et les AVC, les patients et les cliniciens peuvent choisir les bioprotheses valvulaires selon des facteurs comme le risque d'hemorragie et la durabilite de la prothese. Numero d'enregistrement de la recherche : PROSPERO no CRD42017081863, In 2010, more than 2.6 million people worldwide were receiving dialysis for end-stage kidney disease (ESKD), a prevalence that is likely to increase to more than 5.4 million people by [...]
- Published
- 2022
- Full Text
- View/download PDF
16. Cardiovascular Drug Use After Acute Kidney Injury Among Hospitalized Patients With a History of Myocardial Infarction
- Author
-
Meraz-Muñoz, Alejandro Y., Jeyakumar, Nivethika, Luo, Bin, Beaubien-Souligny, William, Chanchlani, Rahul, Clark, Edward G., Harel, Ziv, Kitchlu, Abhijat, Neyra, Javier A., Zappitelli, Michael, Chertow, Glenn M., Garg, Amit X., Wald, Ron, and Silver, Samuel A.
- Published
- 2023
- Full Text
- View/download PDF
17. Association of Primary Versus Rotating Nephrologist Model of Care in Hemodialysis Programs with Patient Outcomes
- Author
-
Yau, Kevin, Jeyakumar, Nivethika, Kang, Yuguang, Dixon, Stephanie N., Freeman, Megan, Garg, Amit X., Harel, Ziv, Sood, Manish M., Thomas, Alison, Wald, Ron, and Silver, Samuel A.
- Published
- 2023
- Full Text
- View/download PDF
18. Predictive Models for Kidney Recovery and Death in Patients Continuing Dialysis as Outpatients after Starting in Hospital
- Author
-
Clark, Edward G., James, Matthew T., Hiremath, Swapnil, Sood, Manish M., Wald, Ron, Garg, Amit X., Silver, Samuel A., Tan, Zhi, and van Walraven, Carl
- Published
- 2023
- Full Text
- View/download PDF
19. COVID-19 vaccine uptake among Ontario physicians: a descriptive population-based retrospective cohort study
- Author
-
Liu, Cheng-Wei, primary, Jeyakumar, Nivethika, additional, McArthur, Eric, additional, Sontrop, Jessica M, additional, Myran, Daniel T, additional, Schwartz, Kevin L, additional, Sood, Manish M, additional, Tanuseputro, Peter, additional, and Garg, Amit X, additional
- Published
- 2024
- Full Text
- View/download PDF
20. Integrating Specialist and Primary Care in Chronic Disease Management
- Author
-
Yazdani, Yasaman, primary, Garg, Amit X., additional, and Zwarenstein, Merrick, additional
- Published
- 2024
- Full Text
- View/download PDF
21. Candidate Kidney Protective Strategies for Patients Undergoing Major Abdominal Surgery: A Secondary Analysis of the RELIEF Trial Cohort
- Author
-
McIlroy, David R., primary, Feng, Xiaoke, additional, Shotwell, Matthew, additional, Wallace, Sophia, additional, Bellomo, Rinaldo, additional, Garg, Amit X., additional, Leslie, Kate, additional, Peyton, Philip, additional, Story, David, additional, and Myles, Paul S., additional
- Published
- 2024
- Full Text
- View/download PDF
22. Association of Blood Mitochondrial DNA Copy Number With Risk of Acute Kidney Injury After Cardiac Surgery
- Author
-
Jotwani, Vasantha, primary, Thiessen-Philbrook, Heather, additional, Arking, Dan E., additional, Yang, Stephanie Y., additional, McArthur, Eric, additional, Garg, Amit X., additional, Katz, Ronit, additional, Tranah, Gregory J., additional, Ix, Joachim H., additional, Cummings, Steve, additional, Waikar, Sushrut S., additional, Sarnak, Mark J., additional, Shlipak, Michael G., additional, Parikh, Samir M., additional, and Parikh, Chirag R., additional
- Published
- 2024
- Full Text
- View/download PDF
23. Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial
- Author
-
Garg, Amit X, Al-Jaishi, Ahmed A, Dixon, Stephanie N, Sontrop, Jessica M, Anderson, Sierra J, Bagga, Amit, Benjamin, Derek S, Berry, William AD, Blake, Peter G, Chambers, Laura C, Chan, Patricia CK, Delbrouck, Nicole F, Devereaux, Philip J, Goluch, Richard J, Gregor, Laura H, Grimshaw, Jeremy M, Hanson, Garth J, Illiescu, Eduard A, Jain, Arsh K, Killin, Lauren, Lok, Charmaine E, Luo, Bin, Mustafa, Reem A, Nathoo, Bharat C, Nesrallah, Gihad E, Oliver, Matt J, Pandeya, Sanjay, Parmar, Malvinder S, Perkins, David N, Presseau, Justin, Rabin, Elijah Z, Sasal, Joanna T, Shulman, Tanya S, Smith, D Michael, Sood, Manish, Steele, Andrew W, Tam, Paul YW, Tascona, Daniel J, Wadehra, Davinder B, Wald, Ron, Walsh, Michael, Watson, Paul A, Wodchis, Walter P, Zager, Philip G, Zwarenstein, Merrick, and McIntyre, Christopher W
- Published
- 2022
- Full Text
- View/download PDF
24. Postdonation eGFR and New-Onset Antihypertensive Medication Use After Living Kidney Donation
- Author
-
Lentine, Krista L, Holscher, Courtenay M, Naik, Abhijit S, Lam, Ngan N, Segev, Dorry L, Garg, Amit X, Axelrod, David, Xiao, Huiling, Henderson, Macey L, Massie, Allan B, Kasiske, Bertram L, Hess, Gregory P, Hsu, Chi-yuan, Park, Meyeon, and Schnitzler, Mark A
- Subjects
Hypertension ,Transplantation ,Clinical Research ,Kidney Disease ,Renal and urogenital - Abstract
BackgroundLimited data are available regarding clinical implications of lower renal function after living kidney donation. We examined a novel integrated database to study associations between postdonation estimated glomerular filtration rate (eGFR) and use of antihypertensive medication (AHM) treatment after living kidney donation.MethodsStudy data were assembled by linking national U.S. transplant registry identifiers, serum creatinine (SCr) values from electronic medical records, and pharmacy fill records for 3222 living donors (1989-2016) without predonation hypertension. Estimated GFR (mL/min per 1.73 m2) was computed from SCr values by the CKD-EPI equation. Repeated measures multivariable mixed effects modeling examined the associations (adjusted odds ratio, 95%LCLaOR95% UCL) between AHM use and postdonation eGFR levels (random effect) with fixed effects for baseline donor factors.ResultsThe linked database identified an average of 3 postdonation SCr values per donor (range: 1-38). Lower postdonation eGFR (vs ≥75) bore graded associations with higher odds of AHM use (eGFR 30-44: aOR 0.951.472.26; 30 kg/m2 (aOR 1.011.452.09), first-degree donor-recipient relationship (aOR 1.071.381.79), "prehypertension" at donation (systolic blood pressure 120-139: aOR 1.101.461.94; diastolic blood pressure 80-89: aOR 1.061.451.99).ConclusionsThis novel linkage illustrates the ability to identify postdonation kidney function and associate it with clinically meaningful outcomes; lower eGFR after living kidney donation is a correlate of AHM treatment requirements. Further work should define relationships of postdonation renal function, hypertension, and other morbidity measures.
- Published
- 2019
25. The Association of Angiogenesis Markers With Acute Kidney Injury and Mortality After Cardiac Surgery
- Author
-
Mansour, Sherry G, Zhang, William R, Moledina, Dennis G, Coca, Steven G, Jia, Yaqi, Thiessen-Philbrook, Heather, McArthur, Eric, Inoue, Kazunori, Koyner, Jay L, Shlipak, Michael G, Wilson, F Perry, Garg, Amit X, Ishibe, Shuta, Parikh, Chirag R, and Consortium, TRIBE-AKI
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Cardiovascular ,Clinical Research ,Kidney Disease ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Aged ,Biomarkers ,Cardiac Surgical Procedures ,Creatinine ,Endpoint Determination ,Female ,Humans ,Kidney ,Male ,Middle Aged ,Neovascularization ,Physiologic ,Outcome Assessment ,Health Care ,Postoperative Complications ,Prospective Studies ,Receptors ,Vascular Endothelial Growth Factor ,Risk Assessment ,United States ,Vascular Endothelial Growth Factor A ,TRIBE-AKI Consortium ,AKI duration ,Acute kidney injury ,VEGF-A ,angiogenesis ,angiogenic growth factor ,biomarker ,cardiac surgery ,cytokine ,mortality ,placental growth factor ,soluble VEGF receptor 1 ,vascular endothelial growth factor A ,Public Health and Health Services ,Urology & Nephrology ,Clinical sciences - Abstract
Rationale & objectiveThe process of angiogenesis after kidney injury may determine recovery and long-term outcomes. We evaluated the association of angiogenesis markers with acute kidney injury (AKI) and mortality after cardiac surgery.Study designProspective cohort.Setting & participants1,444 adults undergoing cardiac surgery in the TRIBE-AKI (Translational Research Investigating Biomarker Endpoints for Acute Kidney Injury) cohort.ExposuresPlasma concentrations of 2 proangiogenic markers (vascular endothelial growth factor A [VEGF] and placental growth factor [PGF]) and 1 antiangiogenic marker (soluble VEGF receptor 1 [VEGFR1]), measured pre- and postoperatively within 6 hours after surgery.OutcomesAKI, long AKI duration (≥7 days), and 1-year all-cause mortality.Analytical approachMultivariable logistic regression.ResultsFollowing cardiac surgery, plasma VEGF concentrations decreased 2-fold, and PGF and VEGFR1 concentrations increased 1.5- and 8-fold, respectively. There were no meaningful associations of preoperative concentrations of angiogenic markers with outcomes of AKI and mortality. Higher postoperative VEGF and PGF concentrations were independently associated with lower odds of AKI (adjusted ORs of 0.89 [95% CI, 0.82-0.98] and 0.69 [95% CI, 0.55-0.87], respectively), long AKI duration (0.65 [95% CI, 0.49-0.87] and 0.48 [95% CI, 0.28-0.82], respectively), and mortality (0.74 [95% CI, 0.62-0.89] and 0.46 [95% CI, 0.31-0.68], respectively). In contrast, higher postoperative VEGFR1 concentrations were independently associated with higher odds of AKI (1.56; 95% CI, 1.31-1.87), long AKI duration (1.75; 95% CI, 1.09-2.82), and mortality (2.28; 95% CI, 1.61-3.22).LimitationsAngiogenesis markers were not measured after hospital discharge, so we were unable to determine long-term trajectories of angiogenesis marker levels during recovery and follow-up.ConclusionsHigher levels of postoperative proangiogenic markers, VEGF and PGF, were associated with lower AKI and mortality risk, whereas higher postoperative antiangiogenic VEGFR1 levels were associated with higher risk for AKI and mortality.
- Published
- 2019
26. Cultivating Innovative Pragmatic Cluster-Randomized Registry Trials Embedded in Hemodialysis Care: Workshop Proceedings From 2018
- Author
-
Lee, Elliot J, Patel, Aakil, Acedillo, Rey R, Bachynski, Jovina C, Barrett, Ian, Basile, Erika, Battistella, Marisa, Benjamin, Derek, Berry, David, Blake, Peter G, Chan, Patricia, Bohm, Clara J, Clemens, Kristin K, Cook, Charles, Dember, Laura, Dirk, Jade S, Dixon, Stephanie, Fowler, Elisabeth, Getchell, Leah, Gholami, Nazanine, Goldstein, Cory, Hahn, Emma, Hogeterp, Betty, Huang, Susan, Hughes, Michelle, Jardine, Meg J, Kalatharan, Shasikara, Kilburn, Shane, Lacson, Eduardo, Leonard, Sean, Liberty, Channing, Lindsay, Craig, MacRae, Jennifer M, Manns, Braden J, McCallum, Janice, McIntyre, Christopher W, Molnar, Amber O, Mustafa, Reem A, Nesrallah, Gihad E, Oliver, Matthew J, Pandes, Michael, Pandeya, Sanjay, Parmar, Malvinder S, Rabin, Elijah Z, Riley, Johnathan, Silver, Samuel A, Sontrop, Jessica M, Sood, Manish M, Suri, Rita S, Tangri, Navdeep, Tascona, Daniel J, Thomas, Alison, Wald, Ron, Walsh, Michael, Weijer, Charles, Weir, Matthew A, Vorster, Hans, Zimmerman, Deborah, and Garg, Amit X
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,Comparative Effectiveness Research ,Assistive Technology ,Kidney Disease ,Bioengineering ,Good Health and Well Being ,chronic kidney disease ,cluster randomized ,hemodialysis ,patient-oriented research ,pragmatic ,randomized controlled trial ,registry-based ,workshop ,Clinical sciences - Abstract
Hemodialysis is a life-sustaining treatment for persons with kidney failure. However, those on hemodialysis still face a poor quality of life and a short life expectancy. High-quality research evidence from large randomized controlled trials is needed to identify interventions that improve the experiences, outcomes, and health care of persons receiving hemodialysis. With the support of the Canadian Institutes of Health Research and its Strategy for Patient-Oriented Research, the Innovative Clinical Trials in Hemodialysis Centers initiative brought together Canadian and international kidney researchers, patients, health care providers, and health administrators to participate in a workshop held in Toronto, Canada, on June 2 and 3, 2018. The workshop served to increase knowledge and awareness about the conduct of innovative, pragmatic, cluster-randomized registry trials embedded into routine hemodialysis care and provided an opportunity to discuss and build support for new trial ideas. The workshop content included structured presentations, facilitated group discussions, and expert panel feedback. Partnerships and promising trial ideas borne out of the workshop will continue to be developed to support the implementation of future large-scale trials.
- Published
- 2019
27. Grams ME, Sang Y, Ballew SH, et al, for the Chronic Kidney Disease Prognosis Consortium. Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93:1442–1451
- Author
-
Astor, Brad, Appel, Lawrence J, Levin, Adeera, Tang, Mila, Djurdjev, Ognjenka, Navaneethan, Sankar D, Jolly, Stacey E, Schold, Jesse D, Nally, Joseph V, Wheeler, David C, Emberson, Jonathan, Townend, John, Landray, Martin, Feldman, Harold I, Hsu, Chi-yuan, Lash, James P, Kalra, Philip A, Ritchie, James P, Maharajan, Raman, Middleton, Rachel J, O’Donoghue, Donal J, Eckardt, Kai-Uwe, Schneider, Markus P, Köttgen, Anna, Kronenberg, Florian, Bärthlein, Barbara, Chang, Alex R, Green, Jamie A, Kirchner, H Lester, Ho, Kevin, Marks, Angharad, Black, Corri, Prescott, Gordon J, Fluck, Nick, Nakayama, Masaaki, Miyazaki, Mariko, Yamamoto, Tae, Yamada, Wang, Angela Yee-Moon, Cheung, Sharon, Wong, Sharon, Chu, Jessie, Wu, Henry, Garg, Amit X, McArthur, Eric, Nash, Danielle M, Shalev, Varda, Chodick, Gabriel, Blankestijn, Peter J, Wetzels, Jack FM, van Zuilen, Arjan D, van den Brand, Jan A, Levey, Andrew S, Inker, Lesley A, Sarnak, Mark J, Tighiouart, Hocine, Zhang, Haitao, Stengel, Benedicte, Metzger, Marie, Flamant, Martin, Houillier, Pascal, Haymann, Jean-Philippe, Rios, Pablo G, Mazzuchi, Nelson, Gadola, Liliana, Lamadrid, Verónica, Sola, Laura, Collins, John F, Elley, C Raina, Kenealy, Timothy, Moranne, Olivier, Couchoud, Cecile, Vigneau, Cecile, Brunskill, Nigel J, Major, Rupert W, Shepherd, David, Medcalf, James F, Kovesdy, Csaba P, Kalantar-Zadeh, Kamyar, Molnar, Miklos Z, Sumida, Keiichi, Potukuchi, Praveen K, Heerspink, Hiddo JL, de Zeeuw, Dick, Brenner, Barry, Carrero, Juan Jesus, Gasparini, Alessandro, Qureshi, Abdul Rashid, Elinder, Carl-Gustaf, Visseren, Frank LJ, van der Graaf, Yolanda, Evans, Marie, Stendahl, Maria, Schön, Staffan, Segelmark, Mårten, Prütz, Karl-Göran, Naimark, David M, Tangri, Navdeep, and Mark, Patrick B
- Subjects
Renal and urogenital ,Chronic Kidney Disease Prognosis Consortium ,Clinical Sciences ,Urology & Nephrology - Abstract
The Chronic Kidney Disease (CKD) Prognosis Consortium is a collaborative author of the above-mentioned article. The CKD Prognosis Consortium investigators/collaborators are as follows: • African American Study of Kidney Disease and Hypertension (AASK): Brad Astor, Lawrence J. Appel; Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT): Adeera Levin, Mila Tang, Ognjenka Djurdjev; Cleveland Clinic CKD Registry Study (CCF): Sankar D. Navaneethan, Stacey E. Jolly, Jesse D. Schold, Joseph V. Nally Jr.; Chronic Renal Impairment in Birmingham (CRIB): David C. Wheeler, Jonathan Emberson, John Townend, Martin Landray; Chronic Renal Insufficiency Cohort Study (CRIC): Harold I. Feldman, Chi-yuan Hsu, James P. Lash, Lawrence J. Appel; Chronic Renal Insufficiency Standards Implementation Study (CRISIS): Philip A. Kalra, James P. Ritchie, Raman Maharajan, Rachel J. Middleton, Donal J. O'Donoghue; German Chronic Kidney Disease Study (GCKD): Kai-Uwe Eckardt, Markus P. Schneider, Anna Köttgen, Florian Kronenberg, Barbara Bärthlein; Geisinger Health System: Alex R. Chang, Jamie A. Green, H. Lester Kirchner, Kevin Ho; Grampian Laboratory Outcomes, Morbidity and Mortality Studies – 2 (GLOMMS2): Angharad Marks, Corri Black, Gordon J. Prescott, Nick Fluck; Gonryo Study: Masaaki Nakayama, Mariko Miyazaki, Tae Yamamoto, Gen Yamada; Hong Kong CKD Studies: Angela Yee-Moon Wang, Sharon Cheung, Sharon Wong, Jessie Chu, Henry Wu; Ontario Institute for Clinical Evaluative Sciences, Provincial Kidney, Dialysis and Transplantation program (ICES KDT): Amit X. Garg, Eric McArthur, Danielle M. Nash; Maccabi Health System: Varda Shalev, Gabriel Chodick; Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practitioner (MASTERPLAN): Peter J. Blankestijn, Jack F.M. Wetzels, Arjan D. van Zuilen, Jan A. van den Brand; Modification of Diet in Renal Disease Study (MDRD): Andrew S. Levey, Lesley A. Inker, Mark J. Sarnak, Hocine Tighiouart; Nanjing CKD Network Cohort Study (Nanjing CKD): Haitao Zhang; NephroTest Study (NephroTest): Benedicte Stengel, Marie Metzger, Martin Flamant, Pascal Houillier, Jean-Philippe Haymann; National Renal Healthcare Program – Uruguay (NRHP-URU): Pablo G. Rios, Nelson Mazzuchi, Liliana Gadola, Verónica Lamadrid, Laura Sola; New Zealand Diabetes Cohort Study (NZDCS): John F. Collins, C. Raina Elley, Timothy Kenealy; Parcours de Soins des Personnes Agées (PSPA): Olivier Moranne, Cecile Couchoud, Cecile Vigneau; Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease (PSP CKD): Nigel J. Brunskill, Rupert W. Major, David Shepherd, James F. Medcalf; Racial and Cardiovascular Risk Anomalies in CKD Cohort (RCAV): Csaba P. Kovesdy, Kamyar Kalantar-Zadeh, Miklos Z. Molnar, Keiichi Sumida, Praveen K. Potukuchi; Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL): Hiddo J.L. Heerspink, Dick de Zeeuw, Barry Brenner; Stockholm CREAtinine Measurements Cohort (SCREAM): Juan Jesus Carrero, Alessandro Gasparini, Abdul Rashid Qureshi, Carl-Gustaf Elinder; Second Manifestations of ARTerial Disease Study (SMART): Frank L.J. Visseren, Yolanda van der Graaf; Swedish Renal Registry CKD Cohort (SRR CKD): Marie Evans, Maria Stendahl, Staffan Schön, Mårten Segelmark, Karl-Göran Prütz; Sunnybrook Cohort: David M. Naimark, Navdeep Tangri; West of Scotland CKD Study: Patrick B. Mark, Jamie P. Traynor, Colin C. Geddes, Peter C. Thomson.• CKD Prognosis Consortium Steering Committee: Alex R. Chang, Josef Coresh (Chair), Ron T. Gansevoort, Morgan E. Grams, Anna Köttgen, Andrew S. Levey, Kunihiro Matsushita, Mark Woodward, Luxia Zhang.• CKD Prognosis Consortium Data Coordinating Center: Shoshana H. Ballew (Assistant Project Director), Jingsha Chen (Programmer), Josef Coresh (Principal Investigator), Morgan E. Grams (Director of Nephrology Initiatives), Lucia Kwak (Programmer), Kunihiro Matsushita (Director), Yingying Sang (Lead Programmer), Aditya Surapaneni (Programmer), Mark Woodward (Senior Statistician).• Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Prognosis and Optimal Management of Patients with Advanced CKD: Kai-Uwe Eckardt (Conference Co-Chair), Brenda R. Hemmelgarn (Conference Co-Chair), David C. Wheeler (KDIGO Co-Chair), Wolfgang C. Winkelmayer (KDIGO Co-Chair), John Davis (CEO), Danielle Green (Managing Director), Michael Cheung (Chief Scientific Officer), Tanya Green (Communications Director), Melissa McMahan (Programs Director).
- Published
- 2018
28. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes
- Author
-
Vasquez-Rios, George, Oh, Wonsuk, Lee, Samuel, Bhatraju, Pavan, Mansour, Sherry G., Moledina, Dennis G., Gulamali, Faris F., Siew, Edward D., Garg, Amit X., Sarder, Pinaki, Chinchilli, Vernon M., Kaufman, James S., Hsu, Chi-yuan, Liu, Kathleen D., Kimmel, Paul L., Go, Alan S., Wurfel, Mark M., Himmelfarb, Jonathan, Parikh, Chirag R., Coca, Steven G., and Nadkarni, Girish N.
- Published
- 2023
- Full Text
- View/download PDF
29. Association of Preoperative Growth Differentiation Factor-15 Concentrations and Postoperative Cardiovascular Events after Major Noncardiac Surgery
- Author
-
Duceppe, Emmanuelle, Borges, Flavia K., Conen, David, Tiboni, Maria, Chan, Matthew T. V., Patel, Ameen, Sessler, Daniel I., Kavsak, Peter A., Ofori, Sandra, Srinathan, Sadeesh, Pearse, Rupert, Jaffe, Allan S., Heels-Ansdell, Diane, Garg, Amit X., Pettit, Shirley, Sapsford, Robert, and Devereaux, P. J.
- Published
- 2023
- Full Text
- View/download PDF
30. Pre-Pregnancy eGFR and the Risk of Adverse Maternal and Fetal Outcomes: A Population-Based Study
- Author
-
Tangren, Jessica, Bathini, Lavanya, Jeyakumar, Nivethika, Dixon, Stephanie N., Ray, Joel, Wald, Ron, Harel, Ziv, Akbari, Ayub, Mathew, Anna, Huang, Susan, Garg, Amit X., and Hladunewich, Michelle A.
- Published
- 2023
- Full Text
- View/download PDF
31. Risk of Acute Kidney Injury After Hypertensive Disorders of Pregnancy: A Population-Based Cohort Study
- Author
-
Shapiro, Joshua, Ray, Joel G., McArthur, Eric, Jeyakumar, Nivethika, Chanchlani, Rahul, Harel, Ziv, Arora, Ritika, Meraz-Munoz, Alejandro, Garg, Amit X., Hladunewich, Michelle, and Wald, Ron
- Published
- 2022
- Full Text
- View/download PDF
32. Machine learning algorithms to identify cluster randomized trials from MEDLINE and EMBASE
- Author
-
Al-Jaishi, Ahmed A., Taljaard, Monica, Al-Jaishi, Melissa D., Abdullah, Sheikh S., Thabane, Lehana, Devereaux, P. J., Dixon, Stephanie N., and Garg, Amit X.
- Published
- 2022
- Full Text
- View/download PDF
33. Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery
- Author
-
Marcucci, Maura, Painter, Thomas W., Conen, David, Leslie, Kate, Lomivorotov, Vladimir V., Sessler, Daniel, Chan, Matthew T. V., Borges, Flavia K., Martínez Zapata, Maria J., Wang, C. Y., Xavier, Denis, Ofori, Sandra N., Landoni, Giovanni, Efremov, Sergey, Kleinlugtenbelt, Ydo V., Szczeklik, Wojciech, Schmartz, Denis, Garg, Amit X., Short, Timothy G., Wittmann, Maria, Meyhoff, Christian S., Amir, Mohammed, Torres, David, Patel, Ameen, Duceppe, Emmanuelle, Ruetzler, Kurtz, Parlow, Joel L., Tandon, Vikas, Wang, Michael K., Fleischmann, Edith, Polanczyk, Carisi A., Jayaram, Raja, Astrakov, Sergey V., Rao, Mangala, VanHelder, Tomas, Wu, William K. K., Cheong, Chao Chia, Ayad, Sabry, Abubakirov, Marat, Kirov, Mikhail, Bhatt, Keyur, de Nadal, Miriam, Likhvantsev, Valery, Iglesisas, Pilar Paniagua, Aguado, Hector J., McGillion, Michael, Lamy, Andre, Whitlock, Richard P., Roshanov, Pavel, Stillo, David, Copland, Ingrid, Vincent, Jessica, Balasubramanian, Kumar, Bangdiwala, Shrikant I., Biccard, Bruce, Kurz, Andrea, Srinathan, Sadeesh, Petit, Shirley, Eikelboom, John, Richards, Toby, Gross, Peter L., Alfonsi, Pascal, Guyatt, Gordon, Belley-Cote, Emily, Spence, Jessica, McIntyre, William, Yusuf, Salim, and Devereaux, P. J.
- Published
- 2022
- Full Text
- View/download PDF
34. Promoting deceased organ and tissue donation registration in family physician waiting rooms (RegisterNow-1): a pragmatic stepped-wedge, cluster randomized controlled registry trial
- Author
-
Li, Alvin Ho-ting, Garg, Amit X., Grimshaw, Jeremy M., Prakash, Versha, Dunnett, Alexie J., Dixon, Stephanie N., Taljaard, Monica, Mitchell, Joanna, Naylor, Kyla L., Faulds, Cathy, Bevan, Rachel, Getchell, Leah, Knoll, Greg, Kim, S. Joseph, Sontrop, Jessica, Tong, Allison, Bjerre, Lise M., Hyjek, Karyn, Currie, Donna, Edwards, Susan, Sullivan, Mike, Harvey-Rioux, Linda, and Presseau, Justin
- Published
- 2022
- Full Text
- View/download PDF
35. Pre-operative kidney biomarkers and risks for death, cardiovascular and chronic kidney disease events after cardiac surgery: the TRIBE-AKI study
- Author
-
Vasquez-Rios, George, Moledina, Dennis G., Jia, Yaqi, McArthur, Eric, Mansour, Sherry G., Thiessen-Philbrook, Heather, Shlipak, Michael G., Koyner, Jay L., Garg, Amit X., Parikh, Chirag R., and Coca, Steven G.
- Published
- 2022
- Full Text
- View/download PDF
36. Rationale and Landscape of Living Kidney Donation in Contemporary Practice
- Author
-
Lam, Ngan N., Sarabu, Nagaraju, Habbous, Steven, Garg, Amit X., Lentine, Krista L., editor, Concepcion, Beatrice P., editor, and Lerma, Edgar V., editor
- Published
- 2021
- Full Text
- View/download PDF
37. Hypertension and Kidney Function After Living Kidney Donation.
- Author
-
Garg, Amit X., Arnold, Jennifer B., Cuerden, Meaghan S., Dipchand, Christine, Feldman, Liane S., Gill, John S., Karpinski, Martin, Klarenbach, Scott, Knoll, Greg, Lok, Charmaine E., Miller, Matthew, Monroy-Cuadros, Mauricio, Nguan, Christopher, Prasad, G. V. Ramesh, Sontrop, Jessica M., Storsley, Leroy, and Boudville, Neil
- Subjects
- *
KIDNEY physiology , *KIDNEY exchange , *DIASTOLIC blood pressure , *KIDNEY transplantation , *HYPERTENSION , *SYSTOLIC blood pressure , *BLOOD pressure - Abstract
Key Points: Question: Do normotensive living kidney donors, compared with nondonors, have a higher risk of hypertension in the first 7 years following donation? Findings: In this 17-center prospective cohort study that included 924 living kidney donors and 396 nondonors, there were no significant between-group differences in the risk of hypertension and no significant between-group differences in mean blood pressure or the change in blood pressure during a median follow-up of 7.3 years. Meaning: After accounting for differences in baseline risk, living donors had a similar risk of hypertension as nondonors in the 7 years following donation and no significant difference in mean blood pressure. Importance: Recent guidelines call for better evidence on health outcomes after living kidney donation. Objective: To determine the risk of hypertension in normotensive adults who donated a kidney compared with nondonors of similar baseline health. Their rates of estimated glomerular filtration rate (eGFR) decline and risk of albuminuria were also compared. Design, Setting, and Participants: Prospective cohort study of 924 standard-criteria living kidney donors enrolled before surgery and a concurrent sample of 396 nondonors. Recruitment occurred from 2004 to 2014 from 17 transplant centers (12 in Canada and 5 in Australia); follow-up occurred until November 2021. Donors and nondonors had the same annual schedule of follow-up assessments. Inverse probability of treatment weighting on a propensity score was used to balance donors and nondonors on baseline characteristics. Exposure: Living kidney donation. Main Outcomes and Measures: Hypertension (systolic blood pressure [SBP] ≥140 mm Hg, diastolic blood pressure [DBP] ≥90 mm Hg, or antihypertensive medication), annualized change in eGFR (starting 12 months after donation/simulated donation date in nondonors), and albuminuria (albumin to creatinine ratio ≥3 mg/mmol [≥30 mg/g]). Results: Among the 924 donors, 66% were female; they had a mean age of 47 years and a mean eGFR of 100 mL/min/1.73 m2. Donors were more likely than nondonors to have a family history of kidney failure (464/922 [50%] vs 89/394 [23%], respectively). After statistical weighting, the sample of nondonors increased to 928 and baseline characteristics were similar between the 2 groups. During a median follow-up of 7.3 years (IQR, 6.0-9.0), in weighted analysis, hypertension occurred in 161 of 924 donors (17%) and 158 of 928 nondonors (17%) (weighted hazard ratio, 1.11 [95% CI, 0.75-1.66]). The longitudinal change in mean blood pressure was similar in donors and nondonors. After the initial drop in donors' eGFR after nephrectomy (mean, 32 mL/min/1.73 m2), donors had a 1.4-mL/min/1.73 m2 (95% CI, 1.2-1.5) per year lesser decline in eGFR than nondonors. However, more donors than nondonors had an eGFR between 30 and 60 mL/min/1.73 m2 at least once in follow-up (438/924 [47%] vs 49/928 [5%]). Albuminuria occurred in 132 of 905 donors (15%) and 95 of 904 nondonors (11%) (weighted hazard ratio, 1.46 [95% CI, 0.97-2.21]); the weighted between-group difference in the albumin to creatinine ratio was 1.02 (95% CI, 0.88-1.19). Conclusions and Relevance: In this cohort study of living kidney donors and nondonors with the same follow-up schedule, the risks of hypertension and albuminuria were not significantly different. After the initial drop in eGFR from nephrectomy, donors had a slower mean rate of eGFR decline than nondonors but were more likely to have an eGFR between 30 and 60 mL/min/1.73 m2 at least once in follow-up. Trial Registration: ClinicalTrials.gov Identifier: NCT00936078 This cohort study aims to determine the risk of hypertension in normotensive adults who donated a kidney compared with nondonors of similar baseline health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Thirty‐day risk of digoxin toxicity among older adults co‐prescribed trimethoprim‐sulfamethoxazole versus amoxicillin: A population‐based cohort study.
- Author
-
Muanda, Flory T., Weir, Matthew A., Ahmadi, Fatemeh, McArthur, Eric, Sontrop, Jessica M., Abdullah, Sheikh S., Urquhart, Brad L., Sadeghi, Hasti, Kim, Richard B., and Garg, Amit X.
- Subjects
DIGOXIN ,OLDER people ,EMERGENCY room visits ,AMOXICILLIN ,ANTIBIOTICS ,COHORT analysis ,BETA lactam antibiotics - Abstract
Importance: Trimethoprim‐sulfamethoxazole (TMP‐SMX) may increase digoxin concentration, a medication with a narrow therapeutic index. Small changes in digoxin concentration could predispose individuals to the risk of toxicity. Objective: To characterize the risk of digoxin toxicity in older adults taking digoxin following co‐prescription of TMP‐SMX compared with co‐prescription of amoxicillin. Design, Settings, and Participants: Retrospective population‐based cohort study in Ontario, Canada (2002–2020) using linked health care data. Participants comprised 47,961 older adults taking digoxin (58% women; median age 80 years [interquartile range 74–86]) who were newly treated with TMP‐SMX (n = 10,273) compared with those newly treated with amoxicillin (n = 37,688). Exposure: Co‐prescription of TMP‐SMX versus amoxicillin in older adults concurrently taking digoxin. Main Outcome and Measure: The primary outcome was a hospital encounter (i.e., hospital admission or emergency department visit) with digoxin toxicity within 30 days of the antibiotic prescription. Inverse probability of treatment weighting on the propensity score was used to balance comparison groups on indicators of baseline health. Weighted risk ratios (RR) were obtained using modified Poisson regression and weighted risk differences (RD) using binomial regression. The number needed to harm (NNH) was calculated as 1/RD. Results: A hospital encounter with digoxin toxicity occurred in 49/10,273 (0.48%) patients treated with TMP‐SMX versus 32/37,688 (0.08%) in those treated with amoxicillin (weighted RR, 5.71 [95% confidence interval (CI), 3.19 to 10.24]; weighted RD, 0.39% [95% CI, 0.25% to 0.53%]; NNH 256 [95% CI, 233 to 400]). Conclusion and Relevance: In older adults taking digoxin, the 30‐day risk of a hospital encounter with digoxin toxicity was nearly 6 times higher in those co‐prescribed TMP‐SMX versus amoxicillin, although the absolute risk difference was low (0.4%). Physicians should prescribe an alternative antibiotic when clinically appropriate. If TMP‐SMX must be co‐prescribed with digoxin (if the benefit is believed to outweigh the risk), digoxin should be dose‐reduced on an individual basis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Mental health and addiction service utilization among people living with chronic kidney disease.
- Author
-
Bhasin, Arrti A, Molnar, Amber O, McArthur, Eric, Nash, Danielle M, Busse, Jason W, Cooper, Rebecca, Heale, Esti, Ip, Jane, Pang, Jocelyn, Blake, Peter G, Garg, Amit X, Kurdyak, Paul, Kim, S Joseph, Sultan, Heebah, and Walsh, Michael
- Subjects
MENTAL health services ,CHRONIC kidney failure ,MENTAL illness ,HEMODIALYSIS facilities ,GLOMERULAR filtration rate - Abstract
Background Mental health problems, particularly anxiety and depression, are common in patients with chronic kidney disease (CKD) and negatively impact quality of life, treatment adherence and mortality. However, the degree to which mental health and addiction services are utilized by those with CKD is unknown. We examined the history of mental health and addiction service use of individuals across levels of kidney function. Methods We performed a population-based cross-sectional study using linked healthcare databases from Ontario, Canada from 2009 to 2017. We abstracted the prevalence of individuals with mental health and addiction service use within the previous 3 years across levels of kidney function [estimated glomerular filtration rate (eGFR) ≥60, 45 to <60, 30 to <45, 15 to <30, <15 ml/min/1.73 m
2 and maintenance dialysis]. We calculated prevalence ratios (PRs) to compare prevalence across kidney function strata, while adjusting for age, sex, year of cohort entry, urban versus rural location, area-level marginalization and Charlson comorbidity index. Results Of 5 956 589 adults, 9% (n = 534 605) had an eGFR <60 ml/min/1.73 m2 or were receiving maintenance dialysis. Fewer individuals with an eGFR <60 ml/min/1.73 m2 had a history of any mental health and addiction service utilization (crude prevalence range 28–31%) compared with individuals with an eGFR ≥60 ml/min/1.73 m2 (35%). Compared with an eGFR ≥60 ml/min/1.73 m2 , the lowest prevalence of individuals with any mental health and addiction service utilization was among those with an eGFR of 15 to <30 ml/min/1.73 m2 {adjusted PR 0.86 [95% confidence interval (CI) 0.85 to 0.88]}, an eGFR <15 ml/min/1.73 m2 [adjusted PR 0.81 (95% CI 0.76–0.86)] and those receiving maintenance dialysis [adjusted PR 0.83 (95% CI 0.81–0.84)]. Less use of outpatient services accounted for differences in service utilization. Conclusions Mental health and addiction service utilization is common but less so in individuals with advanced CKD in Ontario, Canada. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
40. Mental health and addiction health service use by physicians compared to non-physicians before and during the COVID-19 pandemic: A population-based cohort study in Ontario, Canada
- Author
-
Myran, Daniel T., Roberts, Rhiannon, McArthur, Eric, Jeyakumar, Nivethika, Hensel, Jennifer M., Kendall, Claire, Gerin-Lajoie, Caroline, McFadden, Taylor, Simon, Christopher, Garg, Amit X., Sood, Manish M., and Tanuseputro, Peter
- Subjects
Biological sciences - Abstract
Background The Coronavirus Disease 2019 (COVID-19) pandemic has exacerbated mental health challenges among physicians and non-physicians. However, it is unclear if the worsening mental health among physicians is due to specific occupational stressors, reflective of general societal stressors during the pandemic, or a combination. We evaluated the difference in mental health and addictions health service use between physicians and non-physicians, before and during the COVID-19 pandemic. Methods and findings We conducted a population-based cohort study in Ontario, Canada between March 11, 2017 and August 11, 2021 using data collected from Ontario's universal health system. Physicians were identified using registrations with the College of Physicians and Surgeons of Ontario between 1990 and 2020. Participants included 41,814 physicians and 12,054,070 non-physicians. We compared the first 18 months of the COVID-19 pandemic (March 11, 2020 to August 11, 2021) to the period before COVID-19 pandemic (March 11, 2017 to February 11, 2020). The primary outcome was mental health and addiction outpatient visits overall and subdivided into virtual versus in-person, psychiatrists versus family medicine and general practice clinicians. We used generalized estimating equations for the analyses. Pre-pandemic, after adjustment for age and sex, physicians had higher rates of psychiatry visits (aIRR 3.91 95% CI 3.55 to 4.30) and lower rates of family medicine visits (aIRR 0.62 95% CI 0.58 to 0.66) compared to non-physicians. During the first 18 months of the COVID-19 pandemic, the rate of outpatient mental health and addiction (MHA) visits increased by 23.2% in physicians (888.4 pre versus 1,094.7 during per 1,000 person-years, aIRR 1.39 95% CI 1.28 to 1.51) and 9.8% in non-physicians (615.5 pre versus 675.9 during per 1,000 person-years, aIRR 1.12 95% CI 1.09 to 1.14). Outpatient MHA and virtual care visits increased more among physicians than non-physicians during the first 18 months of the pandemic. Limitations include residual confounding between physician and non-physicians and challenges differentiating whether observed increases in MHA visits during the pandemic are due to stressors or changes in health care access. Conclusions The first 18 months of the COVID-19 pandemic was associated with a larger increase in outpatient MHA visits in physicians than non-physicians. These findings suggest physicians may have had larger negative mental health during COVID-19 than the general population and highlight the need for increased access to mental health services and system level changes to promote physician wellness., Author(s): Daniel T. Myran 1,2,3,*, Rhiannon Roberts 1, Eric McArthur 4, Nivethika Jeyakumar 4, Jennifer M. Hensel 5, Claire Kendall 1,2,3,6, Caroline Gerin-Lajoie 7,8, Taylor McFadden 7, Christopher Simon 7, [...]
- Published
- 2023
- Full Text
- View/download PDF
41. Group analysis identifies differentially elevated biomarkers with distinct outcomes for advanced acute kidney injury in cardiac surgery
- Author
-
Lin, Haiqun, Scherzer, Rebecca, Philbrook, Heather Thiessen, Coca, Steven G, Wilson, Francis Perry, Garg, Amit X, Shlipak, Michael G, and Parikh, Chirag R
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Prevention ,Clinical Research ,Kidney Disease ,Patient Safety ,Cardiovascular ,Renal and urogenital ,Good Health and Well Being ,Acute Kidney Injury ,Aged ,Aged ,80 and over ,Biomarkers ,Cardiac Surgical Procedures ,Female ,Humans ,Male ,Middle Aged ,Postoperative Complications ,advanced AKI ,biomarkers of AKI ,group-based analysis ,Medicinal and Biomolecular Chemistry ,Medical Biochemistry and Metabolomics ,Oncology & Carcinogenesis ,Clinical sciences ,Medical biochemistry and metabolomics ,Medicinal and biomolecular chemistry - Abstract
AIM:To investigate early postoperative biomarkers for risk discrimination of advanced acute kidney injury (AKI). MATERIALS & METHODS:Postoperative plasma biomarkers including NGAL, h-FABP, CK-MB, hsTNT, NT-proBNP, IL-6, IL-10 and VEGF were analyzed using group-based method among 426 patients with AKI after cardiac surgery. RESULTS:Six patient groups with distinct biomarker patterns were identified. Individual biomarker displayed significant difference across the groups. The groups showed better discrimination for advanced AKI than any single biomarker either with or without adjusting for clinical variables. Average concentration of a single biomarker within each group, mortality and risk of a secondary outcome all demonstrated an approximately U-shaped relationship with proportion of advanced AKI within each group. CONCLUSION:The group-based analysis revealed that the order of the patient groups with an increasing likelihood of advanced AKI had a nonlinear relationship with average concentration of an individual biomarker, mortality and risk of other outcomes.
- Published
- 2017
42. Effect of Intradialytic Exercise on Cardiovascular Outcomes in Maintenance Hemodialysis: A Systematic Review and Meta-Analysis
- Author
-
Verrelli, Davide, primary, Sharma, Ajaya, additional, Alexiuk, Jamie, additional, Tays, Quinn, additional, Rossum, Krista, additional, Sharma, Monica, additional, Ford, Emilie, additional, Iansavichene, Alla, additional, Al-Jaishi, Ahmed A., additional, Whitlock, Reid, additional, McIntyre, Christopher W., additional, Garg, Amit X., additional, and Bohm, Clara, additional
- Published
- 2024
- Full Text
- View/download PDF
43. Comparison of Acute Health Care Utilization Between Patients Receiving In-Center Hemodialysis and the General Population: A Population-Based Matched Cohort Study From Ontario, Canada
- Author
-
Naylor, Kyla L., primary, Vinegar, Marlee, additional, Blake, Peter G., additional, Bota, Sarah, additional, Luo, Bin, additional, Garg, Amit X., additional, Ip, Jane, additional, Yeung, Angie, additional, Gingras, Joanie, additional, Aziz, Anas, additional, Iskander, Carina, additional, and McFarlane, Phil, additional
- Published
- 2024
- Full Text
- View/download PDF
44. High-Throughput Computing to Automate Population-Based Studies to Detect the 30-Day Risk of Adverse Outcomes After New Outpatient Medication Use in Older Adults with Chronic Kidney Disease: A Clinical Research Protocol
- Author
-
Abdullah, Sheikh S., primary, Rostamzadeh, Neda, additional, Muanda, Flory T., additional, McArthur, Eric, additional, Weir, Matthew A., additional, Sontrop, Jessica M., additional, Kim, Richard B., additional, Kamran, Sedig, additional, and Garg, Amit X., additional
- Published
- 2024
- Full Text
- View/download PDF
45. Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis
- Author
-
Weisman, Alanna, Tomlinson, George A., Lipscombe, Lorraine L., Garg, Amit X., Perkins, Bruce A., Cherney, David Z.I., and Hawker, Gillian A.
- Published
- 2021
- Full Text
- View/download PDF
46. Predicting Myocardial Injury and Other Cardiac Complications After Elective Noncardiac Surgery with the Revised Cardiac Risk Index: The VISION Study
- Author
-
Roshanov, Pavel S., Sessler, Daniel I., Chow, Clara K., Garg, Amit X., Walsh, Michael W., Lam, Ngan N., Hildebrand, Ainslie M., Biccard, Bruce M., Acedillo, Rey R., MacNeil, S. Danielle, Lee, Vincent W., Szczeklik, Wojciech, Mrkobrada, Marko, Thabane, Lehana, and Devereaux, P.J.
- Published
- 2021
- Full Text
- View/download PDF
47. Systematic Review and Meta-Analysis of Preventative Strategies for Acute Kidney Injury in Patients Undergoing Abdominal Aortic Aneurysm Repair
- Author
-
Fernandes, Michaela, Majoni, Melissa, Garg, Amit X., and Dubois, Luc
- Published
- 2021
- Full Text
- View/download PDF
48. Short-and long-term outcomes of sustained low efficiency dialysis vs continuous renal replacement therapy in critically ill patients with acute kidney injury
- Author
-
Harvey, Andrea K., Burns, Karen E.A., McArthur, Eric, Adhikari, Neill K.J., Li, Daniel, Kitchlu, Abhijat, Meraz-Munõz, Alejandro, Garg, Amit X., Nash, Danielle M., Perez-Sanchez, Adic, Beaubien-Souligny, William, Bagshaw, Sean M., Friedrich, Jan O., Silver, Samuel A., and Wald, Ron
- Published
- 2021
- Full Text
- View/download PDF
49. Quality of Diabetes Care in Blended Fee-for-Service and Blended Capitation Payment Systems
- Author
-
Bamimore, Mary Aderayo, Devlin, Rose Anne, Zaric, Gregory S., Garg, Amit X., and Sarma, Sisira
- Published
- 2021
- Full Text
- View/download PDF
50. Donor Family History of ESKD and Long-term Outcomes Among African American Living Kidney Donors: A Retrospective Cohort Study
- Author
-
Ortigosa-Goggins, Mariella, Garg, Amit X., Li, Lihua, and Doshi, Mona D.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.